Rit2 reduces LRRK2 kinase activity and protects against alpha-synuclein neuropathology
Obergasteiger, J.; Castonguay, A.-M.; Frapporti, G.; Lobbestael, E.; Baekelandt, V.; Hicks, A.; Pramstaller, P.; Gravel, C.; Corti, C.; Levesque, M.; Volta, M.
Show abstract
In Parkinsons disease (PD) misfolded alpha-synuclein (aSyn) accumulates in the substantia nigra, where dopaminergic neurons are progressively lost. The mechanisms underlying aSyn pathology are still unclear but hypothesized to involve the autophagy-lysosome pathway (ALP). LRRK2 mutations are a major cause of familial and sporadic PD, hyperactivate kinase activity and its pharmacological inhibition reduces pS129-aSyn inclusions. We observed selective downregulation of the novel PD risk factor RIT2 in G2019S-LRRK2 expressing cells. Here we studied whether RIT2 could modulate LRRK2 kinase activity. RIT2 overexpression in G2019S-LRRK2 cells rescued ALP abnormalities and diminished aSyn inclusions. In vivo, viral mediated overexpression of RIT2 conferred neuroprotection against AAV-A53T-aSyn. Furthermore, RIT2 overexpression prevented the A53T-aSyn-dependent increase of LRRK2 kinase activity in vivo. Our data indicate that RIT2 inhibits overactive LRRK2 to ameliorate ALP impairment and counteract aSyn aggregation and related deficits. Targeting RIT2 could represent a novel strategy to combat neuropathology in familial and idiopathic PD.
Matching journals
The top 2 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Bioenergetic and Protein Processing Imbalances Synergize in iPSC-Dopamine neurons from Individuals with Idiopathic Parkinsons Disease 97%
- Neuropathology in an α-synuclein preformed fibril mouse model occurs independent of the Parkinson's disease-linked lysosomal ATP13A2 protein 96%
- A double-hit in vivo model of GBA1 viral microRNA-mediated downregulation and human alpha-synuclein overexpression demonstrates nigrostriatal degeneration 96%
Similar papers in this journal
- Dopamine and cortical iPSC-derived neurons with different Parkinsonian mutations show variation in lysosomal and mitochondrial dysfunction: implications for protein deposition versus selective cell loss 96%
- The activities of LRRK2 and GCase are positively correlated in clinical biospecimens and experimental models of Parkinson's disease 96%
- Introducing PIGMO, a novel PIGmented MOuse model of Parkinson's disease 95%
Similar papers in this journal
Similar papers in this journal
- Pathogenic LRRK2 control of primary cilia and Hedgehog signaling in neurons and astrocytes of mouse brain 95%
- Exploring therapeutic strategies for Infantile Neuronal Axonal Dystrophy (INAD/PARK14) 95%
- The LRRK2 G2019S mutation alters astrocyte-to-neuron communication via extracellular vesicles and induces neuron atrophy in a human iPSC-derived model of Parkinson's disease 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.